



05-06-03

1644
CASE 4-30443B \$

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 268930-26515

Express Mail Label Number

5/5-12 03 3

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

MAY 09 2003

TECH CENTER 1600/2900

IN RE APPLICATION OF

Art Unit: 1644

FARRIES ET AL.

APPLICATION NO: 09/875,519

FILED: JUNE 6, 2001

FOR: DOWN-REGULATED RESISTANT C3 CONVERTASE

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c). A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Hesna J. Pfeiffer
Attorney for Applicants
Reg. No. 22,640

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(862) 778-7903

Date: May 5, 2003



CASE 4-30443B

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV26893056505
Express Mail Label Number

5/5/2003
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

MAY 09 2003

TECH CENTER 1600/2900

IN RE APPLICATION OF

Art Unit: 1644

FARRIES ET AL.

APPLICATION NO: 09/875,519

FILED: JUNE 6, 2001

FOR: DOWN-REGULATED RESISTANT C3 CONVERTASE

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis Corporation in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis Corporation.

Respectfully submitted,

Hesna J. Pfeffer
Attorney for Applicants
Reg. No. 22,640


Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(862) 778-7903
Date: May 5, 2003

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-304438
APPLICATION NO.
09/875,519
APPLICANT
FARRIES ET AL.
FILING DATE
JUNE 6, 2001RECEIVED
MAY 09 2003
Group
1644

TECH CENTER 1600/2900



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM						<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	McNearney, TA, J. Exp. Med. (1987) 166:1525-35
	AS	Nicol, PAE (1973) Immunol.24:259-275
	AT	Pangburn, MK (1984) Springer Semin. Immunopathol. 7: 163-92
	AU	Kotwal, GJ Nature (1988)335 (6186): 176-8

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.